{"data":[{"EU CT nr":"2022-501254-10-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Uuringu nimetus":"A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab","Haigusseisund":"Advanced tumors","Uuringukeskused":"Tartu Ülikooli Kliinikum","Lasteuuring":"Ei"},{"EU CT nr":"2022-501480-41-00","Uuringu sponsor":"Sun Pharmaceutical Industries Limited","Uuringu nimetus":"An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis","Haigusseisund":"Psoriatic Arthritis","Uuringukeskused":"MediTrials OÜ, Kliiniliste Uuringute Keskus OÜ, Innomedica OÜ","Lasteuuring":"Ei"},{"EU CT nr":"2022-502077-42-00","Uuringu sponsor":"Sunovion Pharmaceuticals Inc.","Uuringu nimetus":"A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder","Haigusseisund":"Generalised anxiety disorder","Uuringukeskused":"Marienthali Kliinik OÜ, Tartu Ülikooli Kliinikum","Lasteuuring":"Ei"},{"EU CT nr":"2023-503501-11-00","Uuringu sponsor":"Merck Sharp & Dohme LLC","Uuringu nimetus":"An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator- Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTED46/EVOKE-03)","Haigusseisund":"Metastatic Non-small Cell Lung Cancer","Uuringukeskused":"Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-503631-18-01","Uuringu sponsor":"Sanofi-Aventis Research & Development","Uuringu nimetus":"An interventional, Phase 3 extension study to investigate long-term safety and tolerability of tolebrutinib in participants with relapsing multiple sclerosis, primary progressive multiple sclerosis, or nonrelapsing secondary progressive multiple sclerosis","Haigusseisund":"Progressive relapsing multiple sclerosis, Secondary progressive multiple sclerosis, Relapsing multiple sclerosis","Uuringukeskused":"Tartu Ülikooli Kliinikum, Clinic4U OÜ","Lasteuuring":"Ei"},{"EU CT nr":"2023-503655-10-00","Uuringu sponsor":"Abbvie Deutschland GmbH & Co. KG","Uuringu nimetus":"SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Moderately to Severely Active SLE","Haigusseisund":"Systemic Lupus Erythematosus (SLE)","Uuringukeskused":"Innomedica OÜ, MediTrials OÜ, Põhja-Eesti Regionaalhaigla, Ida-Tallinna Keskhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-505438-85-00","Uuringu sponsor":"Idorsia Pharmaceuticals Ltd.","Uuringu nimetus":"Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction","Haigusseisund":"Acute myocardial infarction (AMI)","Uuringukeskused":"Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-506813-23-00","Uuringu sponsor":"Tartu Ülikooli Kliinikum","Uuringu nimetus":"A Phase 2, double-blind, placebo-controlled, randomized, proof-of-concept study evaluating LSTA1 when added to standard of care (temozolomide) versus temozolomide and matching LSTA1 placebo in subjects with newly diagnosed Glioblastoma Multiforme (GBM)","Haigusseisund":"Glioblastoma Multiforme","Uuringukeskused":"Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-506917-23-00","Uuringu sponsor":"Cosmo Technologies Limited","Uuringu nimetus":"Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solution administered by enema to patients with mild to moderate left-sided ulcerative colitis","Haigusseisund":"patients with mild to moderate left-sided ulcerative colitis","Uuringukeskused":"Tartu Ülikooli Kliinikum, Lääne-Tallinna Keskhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2024-513304-33-00","Uuringu sponsor":"Diamyd Medical AB","Uuringu nimetus":"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults with Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype","Haigusseisund":"Type 1 diabetes mellitus","Uuringukeskused":"Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla, Liina Viitas OÜ","Lasteuuring":"Jah"},{"EU CT nr":"2023-503265-27-00","Uuringu sponsor":"Glaxosmithkline Research & Development Limited","Uuringu nimetus":"A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","Haigusseisund":"Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","Uuringukeskused":"Põhja-Eesti Regionaalhaigla, Tartu Ülikooli Kliinikum, Ida-Tallinna Keskhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-505053-40-00","Uuringu sponsor":"Lillebaelt Hospital","Uuringu nimetus":"Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD","Haigusseisund":"Multiple Myeloma","Uuringukeskused":"sihtasutus Põhja-Eesti Regionaalhaigla  ","Lasteuuring":"Ei"},{"EU CT nr":"2022-502746-27-00","Uuringu sponsor":"AstraZeneca AB","Uuringu nimetus":"A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)","Haigusseisund":"Endometrial Cancer","Uuringukeskused":"Tartu Ülikooli Kliinikum, Ida-Tallinna Keskhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-507353-15-00","Uuringu sponsor":"Boehringer Ingelheim Espana S.A.\nBoehringer Ingelheim RCV GmbH & Co. KG\nBoehringer Ingelheim International GmbH","Uuringu nimetus":"An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)","Haigusseisund":"progressive pulmonary fibrosis (PPF), idiopathic pulmonary fibrosis (IPF)","Uuringukeskused":"Põhja-Eesti Regionaalhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2024-513009-30-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG","Uuringu nimetus":"A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderate to Severe Crohn’s Disease","Haigusseisund":"Moderate to Severe Crohn’s Disease","Uuringukeskused":"Ida-Tallinna Keskhaigla, Tartu Ülikooli Kliinikum, Aktsiaselts Medicum Tervishoiuteenused","Lasteuuring":"Ei"},{"EU CT nr":"2024-514135-17-00","Uuringu sponsor":"Alpine Immune Sciences Inc.","Uuringu nimetus":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy (RAINIER).","Haigusseisund":"Immunoglobulin A Nephropathy","Uuringukeskused":"Tartu Ülikooli Kliinikum, sihtasutus Põhja-Eesti Regionaalhaigla","Lasteuuring":"Ei"},{"EU CT nr":"2023-509197-35-00","Uuringu sponsor":"Argenx","Uuringu nimetus":"A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease","Haigusseisund":"Thyroid Eye Disease (TED)","Uuringukeskused":"Tartu Ülikooli Kliinikum, Liina Viitas OÜ","Lasteuuring":"Ei"},{"EU CT nr":"2024-516240-26-00","Uuringu sponsor":"Moderna Inc.","Uuringu nimetus":"A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age","Haigusseisund":"Influenza","Uuringukeskused":"Kliiniliste Uuringute Keskus OÜ, Merelahe TK OÜ, Innomedica OÜ, Center for Clinical and Basic Research AS, Vee Perearstikeskus OÜ","Lasteuuring":"Ei"},{"EU CT nr":"2023-505678-14-00","Uuringu sponsor":"AbbVie Deutschland GmbH & Co. KG","Uuringu nimetus":"A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis","Haigusseisund":"Ulcerative Colitis","Uuringukeskused":"Sihtasutus Pärnu Haigla, Tartu Ülikooli Kliinikum, Lääne-Tallinna Keskhaigla AS, Aktsiaselts Medicum Tervishoiuteenused","Lasteuuring":"Ei"},{"EU CT nr":"2023-504876-12-00","Uuringu sponsor":"Theravance Biopharma Ireland Limited","Uuringu nimetus":"A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy","Haigusseisund":"Neurogenic Orthostatic Hypotension","Uuringukeskused":"Astra Kliinik, Tartu Ülikooli Kliinikum","Lasteuuring":"Ei"}],"metadata":{"total":41,"mimetype":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"}}